_20240711181419_original_image_35.webp)
Pharmazz Inc., a biopharmaceutical company headquartered in Willowbrook, Illinois, USA, is making significant strides in the field of critical care medicine. Led by the visionary Anil Gulati, Chairman and CEO, Pharmazz is not only developing life-saving drugs but also working towards making them accessible to patients globally. In an exclusive interview with BW Healthcare World, Dr. Gulati discussed Pharmazz's groundbreaking work, future plans, and the intricacies of navigating the drug development landscape in India.
Global Accessibility of Centhaquine: A Resuscitative Agent for Hypovolemic Shock
Centhaquine, a drug developed by Pharmazz, holds immense promise for treating hypovolemic shock, a condition where the body loses a large amount of fluids. Gulati acknowledged this potential, stating, "Centhaquine's global potential is undeniable. To ensure it reaches patients worldwide, we've secured manufacturing and marketing authorization for the drug in India. Additionally, Dr. Reddy's Laboratories, a renowned pharmaceutical company, handles sales and distribution within the country." This strategic partnership ensures that Centhaquine reaches those in critical need across India.
Gulati further elaborated on Pharmazz's commitment to bringing Centhaquine to a wider patient pool. He revealed, "We have received approval from the US Food and Drug Administration (FDA) to conduct crucial Phase III clinical trials for Centhaquine. The success of these trials will pave the way for marketing authorization in the USA." He added, "To expedite this process, Pharmazz has assembled a team of world-renowned investigators in critical care medicine. Scientific advisory committee meetings are also underway to strategise for the global trials."
Sovateltide's Success in India and the Future of Neurological Treatments
Sovateltide, another groundbreaking drug by Pharmazz, has already received marketing approval in India for treating acute cerebral ischemic stroke. This success story serves as a springboard for Pharmazz's future endeavours in the neurological treatment domain. Gulati unveiled the company's ongoing efforts, stating, "Building on the success of Sovateltide, Pharmazz is currently conducting Phase II clinical trials for the drug on various neurological conditions. These include Hypoxic ischemic encephalopathy (HIE) in newborns, Alzheimer's disease, and Spinal Cord Injury." The promising results from these trials could lead to significant advancements in treating these debilitating neurological conditions.
Balancing Innovation with Affordability: Reaching Underserved Regions
Balancing innovation with affordability is a crucial challenge in the healthcare industry. Gulati addressed this concern by highlighting Pharmazz's strategic approach. "Ensuring affordability and accessibility of our drugs is paramount," he asserted. He explained, "To achieve this goal, Pharmazz has entered into licensing agreements with Sun Pharmaceuticals for Sovateltide and Dr. Reddy's Laboratories for Centhaquine. The extensive reach of these pharmaceutical giants ensures that our drugs reach not just major cities but also underserved regions throughout India." This strategic partnership allows Pharmazz to bridge the gap between innovation and affordability, making their life-saving treatments accessible to a wider population.
Bridging the Gap Between Scientific Discovery and Patient Care
The drug development process is often lengthy, creating a time lag between scientific discovery and the drugs reaching patients. Gulati acknowledged these challenges, stating, "The journey from a laboratory discovery to a life-saving medication is fraught with complexities. High costs, technical expertise, and navigating regulatory environments are just a few of the hurdles that need to be overcome." He elaborated on Pharmazz's approach to bridge this gap, "In just about 10-12 years, Pharmazz has successfully launched two New Chemical Entities (NCEs) in India – Sovateltide and Centhaquine. This achievement is a testament to our persistence and unwavering commitment to research and development." Gulati further emphasised Pharmazz's global aspirations, stating, "We are now planning to expand the market for these drugs to other countries worldwide." The upcoming Phase III trials for both Sovateltide and Centhaquine in the US are a significant step in this direction.
Shaping the Future of Biopharmaceutical Research in India
Gulati, with his vast experience, also offered his insights on the future of biopharmaceutical research in India. He emphasized the importance of collaboration, stating, "By fostering a collaborative approach, pharmaceutical companies can collectively leverage their expertise and resources. This collaborative spirit can drive innovation, enhance regulatory compliance, improve market access, and ultimately reduce costs." If pharmaceutical companies in India join forces, it can significantly accelerate the development and accessibility of life-saving drugs, he added.
Challenges and the Road Ahead for Pharmazz
The quest to develop life-saving drugs is not without its challenges. Gulati shed light on the biggest hurdles Pharmazz faces in navigating the drug development process. These challenges include:
High Cost of R&D: Research and development (R&D) is a cornerstone of innovation in the pharmaceutical industry, but it's also an expensive endeavor. Gulati acknowledged this challenge, highlighting the need for efficient resource allocation and strategic partnerships to make R&D more sustainable.
Lack of Technical Skills: A skilled workforce is essential for successful drug development. Gulati pointed out the need to bridge the gap in technical expertise within the Indian pharmaceutical landscape. He emphasised the importance of investing in education and training programs to create a robust talent pool.
Complex Regulatory Environment: Navigating the regulatory environment for drug development can be a labyrinthine process. Gulati shed light on the complexities arising from variations in regulations across different countries. He advocated for streamlined and standardised regulatory processes to expedite drug development and approval.
Differences in Sales and Distribution Systems: The effectiveness of a drug hinges not just on its development but also on its accessibility to patients.Gulati highlighted the challenges associated with navigating the diverse sales and distribution systems across different countries. He emphasised the need for forging strategic partnerships with established pharmaceutical companies, like Pharmazz has done in India, to ensure wider market reach.
Insurance and Payment Complexities: Even with accessible drugs, navigating insurance coverage and payment complexities can be a barrier for patients. Gulati acknowledged this challenge and called for collaborative efforts between pharmaceutical companies, healthcare providers, and policymakers to develop solutions that ensure affordability for patients.
